The opportunity
Checkpoint inhibitors changed the standard of care in advanced melanoma, but many patients still do not achieve durable benefit. About half of patients experience minimal or no response, and a meaningful proportion of initial responders later relapse, leaving a large population with limited treatment options.
Significant unmet need
There are still no approved therapies that directly address checkpoint inhibitor resistance in melanoma. As the use of immunotherapy expands, so does the need for treatments that can restore response in resistant disease rather than simply add another layer to the same pathway.
-
Increased memory T-cell infiltration in secondary tumors.
-
Evidence consistent with durable immune activation.
-
Supports the rationale for longer-lasting immunotherapy benefit.
Why PMJ2
PMJ2 is being developed as a first-in-class small-molecule immunotherapy designed to restore sensitivity to checkpoint inhibitors in resistant tumors. Unlike more complex cell or viral approaches, PMJ2 offers the potential advantages of a non-viral, scalable modality that is intended to enhance existing checkpoint therapies rather than replace them.
Differentiated by design
Many next-generation immuno-oncology strategies focus on adding more checkpoints, more biologics, or more complex therapeutic platforms. Claredele is taking a different approach: targeting the biology of resistance itself and doing so with a small-molecule program designed for combination use, translational efficiency, and strategic fit with established immunotherapy franchises. Focused today, expandable tomorrow
Claredele’s initial development path is advanced melanoma, where checkpoint inhibitors are standard of care and resistance remains a major clinical challenge.
Over time, the same therapeutic thesis may support expansion into additional cancers and orphan oncology settings where immunotherapy resistance remains a barrier to durable benefit.
Why now
Melanoma incidence continues to rise, the use of checkpoint inhibitors remains broad, and the commercial burden of resistant disease is significant. The deck frames this opportunity as an $830 million target segment within checkpoint-inhibitor-resistant melanoma, supported by a broader melanoma therapeutics market and growing demand for effective combination strategies.
Built for partnership
Claredele is building PMJ2 to complement existing checkpoint inhibitor franchises, creating a natural fit for strategic partners in immuno-oncology. With published science, patent-backed protection, early translational rationale, and a small-molecule profile, the program is positioned for a capital-efficient path toward IND, early clinical proof of concept, and potential partnership.
Get in touch
We welcome inquiries from investors interested in early-stage oncology innovation and the development of PMJ2 for resistant melanoma and beyond.